Related Experiment Video
Updated: Mar 9, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED
Ling Li1, Hailong Zhang1, Man Zhang1
1China Novartis Institutes for BioMedical Research, Shanghai, China.
Abstract:
Polycomb repressive complex 2 (PRC2), a histone H3 lysine 27 methyltransferase, plays a key role in gene regulation and is a known epigenetics drug target for cancer therapy. The WD40 domain-containing protein EED is the regulatory subunit of PRC2. It binds to the tri-methylated lysine 27 of the histone H3 (H3K27me3), and through which stimulates the activity of PRC2 allosterically. Recently, we disclosed a novel PRC2 inhibitor EED226 which binds to the K27me3-pocket on EED and showed strong antitumor activity in xenograft mice model. Here, we further report the identification and validation of four other EED binders along with EED162, the parental compound of EED226. The crystal structures for all these five compounds in complex with EED revealed a common deep pocket induced by the binding of this diverse set of compounds. This pocket was created after significant conformational rearrangement of the aromatic cage residues (Y365, Y148 and F97) in the H3K27me3 binding pocket of EED, the width of which was delineated by the side chains of these rearranged residues. In addition, all five compounds interact with the Arg367 at the bottom of the pocket. Each compound also displays unique features in its interaction with EED, suggesting the dynamics of the H3K27me3 pocket in accommodating the binding of different compounds. Our results provide structural insights for rational design of novel EED binder for the inhibition of PRC2 complex activity.
Insights
Researchers identified new Polycomb repressive complex 2 (PRC2) inhibitors that bind to the EED protein. Structural analysis reveals a common deep pocket formed by compound binding, offering insights for developing novel cancer therapies targeting PRC2.
Area of Science:
- Epigenetics
- Structural Biology
- Drug Discovery
Background:
- Polycomb repressive complex 2 (PRC2) is a key epigenetic regulator and cancer drug target.
- EED is a regulatory subunit of PRC2, binding H3K27me3 to allosterically stimulate PRC2 activity.
- Previous work identified EED226 as a PRC2 inhibitor with antitumor activity.
Purpose of the Study:
- To identify and validate new EED binders as PRC2 inhibitors.
- To elucidate the structural basis of EED-inhibitor interactions.
- To provide insights for rational drug design targeting PRC2.
Main Methods:
- Identification and validation of novel EED binders.
- X-ray crystallography to determine the structures of EED in complex with five compounds.
- Analysis of compound-protein interactions and conformational changes.
Main Results:
- Five new EED binders were identified, including EED162 (parental compound of EED226).
- Crystal structures revealed a common deep pocket formed by compound binding, induced by conformational rearrangement of aromatic residues (Y365, Y148, F97).
- All compounds interacted with Arg367, and unique interactions were observed for each compound, highlighting the pocket's dynamic nature.
Conclusions:
- The identified compounds are potent EED binders with potential as PRC2 inhibitors.
- The structural insights reveal a druggable deep pocket formed by conformational changes in EED.
- These findings support the rational design of novel EED binders for PRC2 inhibition in cancer therapy.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Position-effect Variegation

